SLU-PP-332 Capsules

SLU-PP-332 Capsules deliver an oral compound that activates estrogen-related receptors (ERRα, ERRβ, ERRγ); nuclear receptors that regulate mitochondrial energy metabolism and fat utilization. By activating these receptors, SLU-PP-332 produces gene expression changes in skeletal muscle and metabolic tissue that mirror those induced by endurance exercise at the cellular level. It is a research-stage compound studied for metabolic optimization, fat metabolism, mitochondrial efficiency, and cardiometabolic health.

Exercise induces metabolic adaptations in skeletal muscle by activating energy-sensing pathways that shift the body toward fat oxidation, mitochondrial biogenesis, and improved metabolic flexibility. SLU-PP-332 activates ERR receptors that govern these same downstream gene expression changes; producing the molecular signature of endurance exercise in metabolic tissue without the mechanical stimulus.

Research in animal models has documented improvements in fat metabolism, mitochondrial function, and metabolic efficiency; the compound is in ongoing research and development as a metabolic therapeutic.

SLU-PP-332 Capsules are available as a combination with BAM-15; a mitochondrial uncoupler that promotes fat oxidation by reducing the efficiency of mitochondrial energy conversion, causing the body to burn more calories as heat. SLU-PP-332 activates the metabolic pathways associated with fat utilization; BAM-15 increases the thermogenic demand placed on those pathways simultaneously. Your RegenMD provider will determine whether the combination formulation is appropriate based on your metabolic profile and goals.